Literature DB >> 14648465

Adherence to heroin dependence therapies and human immunodeficiency virus/acquired immunodeficiency syndrome infection rates among drug abusers.

Silvana De Castro1, Eduardo Sabaté.   

Abstract

Adherence is a primary determinant of treatment effectiveness; thus, poor adherence attenuates optimum clinical benefit. A bibliographic review was conducted to evaluate the impact of adherence to heroin dependence treatment on human immunodeficiency virus (HIV) transmission and to identify interventions proven to be effective in improving adherence. The best adherence rates were achieved by methadone and diacetylmorphine, both of which are comparable in promoting significant reduction in heroin use. Methadone adjusted-dose studies with daily doses ranging from 100 to 200 mg and multiple support interventions achieved the highest adherence rates. Studies of methadone maintenance that examined changes in HIV prevalence of infection have found that higher treatment adherence is correlated with a reduction in HIV transmission. These data suggest that patients who adhere continuously to methadone treatment are less likely to continue injecting illicit drugs and sharing contaminated injection equipment than are those who interrupt treatment, thus preventing the spread of HIV via drug injection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648465     DOI: 10.1086/377561

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Authors:  Pria Anand; Sandra A Springer; Michael M Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2010-12

2.  Effects of cognitive impairment on substance abuse treatment attendance: predictive validation of a brief cognitive screening measure.

Authors:  Marc L Copersino; David J Schretlen; Garrett M Fitzmaurice; Scott E Lukas; Judith Faberman; Jody Sokoloff; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-26       Impact factor: 3.829

Review 3.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Authors:  Brian R Edlin; Thomas F Kresina; Daniel B Raymond; Michael R Carden; Marc N Gourevitch; Josiah D Rich; Laura W Cheever; Victoria A Cargill
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 4.  Molecular targets of opiate drug abuse in neuroAIDS.

Authors:  K F Hauser; N El-Hage; S Buch; J R Berger; W R Tyor; A Nath; A J Bruce-Keller; P E Knapp
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.